We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.
- Authors
Cyrenne, Benoit M.; Gibson, Juliet Fraser; Subtil, Antonio; Girardi, Michael; Isufi, Iris; Seropian, Stuart; Foss, Francine
- Abstract
<bold>Background: </bold>Primary cutaneous aggressive epidermotropic cytotoxic CD8 positive T-cell lymphoma (CD8+ PCAETL) is a rare subtype of peripheral T-cell lymphoma with poor outcomes and without a standardized treatment strategy. Allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a potential curative therapy.<bold>Patients and Methods: </bold>We conducted a retrospective case series. We identified 8 patients with the diagnosis of CD8+ PCAETL, 4 of whom also underwent allogeneic HSCT.<bold>Results: </bold>Eight patients were treated at our center with combination chemotherapy and several novel agents, including histone deacetylase inhibitors, brentuximab, and pralatrexate. Patients underwent a median of 8.5 treatments before HSCT. Six of the 8 patients examined, including all 4 who received an HSCT, were alive at their last follow-up.<bold>Conclusion: </bold>Allogeneic HSCT is a promising treatment modality for CD8+ PCAETL. Because of the aggressive nature of this disease and lack of sustained remission with currently available therapies, HSCT should be considered early in the course of treatment. Two novel agents, brentuximab and pralatrexate, showed significant activity against CD8+ PCAETL, and may be incorporated earlier in the treatment course.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2018, Vol 18, Issue 1, pe85
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2017.11.004